Abstract: The present invention relates to an NF-?B inhibitor or a pharmaceutically acceptable salt or prodrug thereof for use in treating lymphoma, wherein said use further comprises administration of at least one agent activating the intrinsic pathway of apoptosis; and to an agent activating the intrinsic pathway of apoptosis or a pharmaceutically acceptable salt or prodrug thereof for use in treating lymphoma, wherein said use further comprises administration of at least one NF-?B inhibitor. The present invention further relates to combined preparations, medicaments, kits, and methods related thereto.